Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Overview
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Companies Involved in Therapeutics Development
Baergic Bio Inc
Cerevel Therapeutics Holdings Inc
Engrail Therapeutics Inc
Sanio AB
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Drug Profiles
BAER-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
darigabat - Drug Profile
Product Description
Mechanism Of Action
History of Events
NCT-10004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SAN-711 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Agonize GABR for Neuropathic Pain and Fibromyalgia - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Dormant Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Discontinued Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Product Development Milestones
Featured News & Press Releases
Mar 24, 2022: Sanio initiates positron emission tomography (PET) stage of SAN711 phase 1 clinical trial
Mar 24, 2022: Sanio initiates positron emission tomography (PET) stage of SAN711 phase 1 clinical trial
Feb 15, 2022: Cerevel Therapeutics announces positive topline results for Darigabat in phase 1 clinical trial in acute anxiety
Feb 10, 2022: Sanio initiates multiple ascending dose stage of SAN711 phase 1 clinical trial
Aug 31, 2021: BioStock: Sanio’s clinical and regulatory progress during H1
Jun 30, 2021: Sanio initiates phase 1 clinical trial of SAN711
Jun 08, 2021: Sanio to present preclinical data on SAN711 at the 7th Congress of the European Academy of Neurology
Jan 28, 2021: Cerevel Therapeutics hosts Iugural Virtual R&D event to review Darigabat (CVL-865) and provide overview of key preclinical programs
Oct 06, 2020: Cerevel Therapeutics announces first patient dosed in phase 2 trial of CVL-865, an investigatiol therapy in development for the treatment of Epilepsy
Dec 08, 2019: Cerevel Therapeutics announces phase 1 results for CVL-865, a Novel a2/3/5-subtype GABAA Positive Allosteric Modulator in Development to treat Epilepsy
Nov 25, 2019: Cerevel Therapeutics to present safety, tolerability, and pharmacokinetics results from phase 1 trial of CVL-865
Apr 09, 2019: Cerevel Therapeutics announces publication of phase 2a study results in Neurology on its most advanced investigatiol Epilepsy treatment
Feb 18, 2019: Sanios SAN711 selected for clinical studies in itching and pain
Feb 13, 2019: NeuroCycle Therapeutics receives NIH SBIR Grant to study Dravet Syndrome drug candidate NCT10004
Dec 04, 2017: Sanio Selects Preclinical Candidate in GABAA a2/a3 Program for Neuropathic Pain and Chronic Itching
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Baergic Bio Inc, 2022
Pipeline by Cerevel Therapeutics Holdings Inc, 2022
Pipeline by Engrail Therapeutics Inc, 2022
Pipeline by Saniona AB, 2022
Dormant Projects, 2022
Discontinued Products, 2022